Mitochondrial pharmacology: Its future is now

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 6, 2014, Pages 629-633

  Szeto, H H ^a   James, L P ^b   Atkinson, A J ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CARDIOLIPIN; CYCLOPHILIN D; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; UBIQUINONE;

AGING; APOPTOSIS; ARTICLE; CELL DEATH; CELL FUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENZYME SYNTHESIS; HOMEOSTASIS; HUMAN; MITOCHONDRIAL GENE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL PHARMACOLOGY; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PHARMACOLOGY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL DISEASES; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 84925549579     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.177     Document Type: Article

References (25)

1. Vafai, S.B. & Mootha, V.K. Mitochondrial disorders as windows into an ancient organelle. Nature 491, 374-383 (2012).
2. Wallace, D.C. A mitochondrial bioenergetic etiology of disease. J. Clin. Invest. 123, 1405-1412 (2013).
3. Zhang, M., Mileykovskaya, E. & Dowhan, W. Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J. Biol. Chem. 277, 43553-43556 (2002).
4. Birk, A.V., Chao, W.M., Bracken, C., Warren, J.D. & Szeto, H.H. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br. J. Pharmacol. 171, 2017-2018 (2014).
5. Petrosillo, G., Casanova, G., Matera, M., Ruggiero, F.M. & Paradies, G. Synergistic effect of Ca2+ and peroxidized cardiolipin in the induction of permeability transition and cytochrome c release in rat heart mitochondria. Ital. J. Biochem. 56, 307-309 (2007).
6. Schug, Z.T. & Gottlieb, E. Cardiolipin acts as a mitochondrial signaling platform to launch apoptosis. Biochim. Biophys. Acta 1788, 2022-2031 (2009).
7. Halestrap, A.P. What is the mitochondrial permeability transition pore? J. Mol. Cell Cardiol. 46, 821-831 (2009).
8. Elrod, J.W. & Molkentin, J.D. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ. J. 77, 1111-1122 (2013).
9. Bonora, M. et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene, e-pub ahead of print 14 April 2014.
10. Szeto, H.H. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol. 171, 2014). 2029-2050 (2014).
11. Smith, R.A.J., Hartley, R.D., Cochemé, H.M. & Murphy, M.P. Mitochondrial pharmacology. Trends Pharmacol. Sci. 33, 341-352 (2012).
12. Ernster, L., Ikkos, D. & Luft, R. Enzymic activities of human skeletal muscle mitochondria: a tool in clinical metabolic research. Nature 184, 1851-1854 (1959).
13. Wallace, K.B. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 29, 361-366 (2008).
14. Than, T.A., Win, S. & Kaplowitz, N. In vitro assays of mitochondrial function/dysfunction Clin. Pharmacol. Ther. 96, 665-668 (2014).
15. Potgieter, M., Pretorius, E. & Pepper, M.S. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr. Rev. 71, 180-188 (2011).
16. Szeto, H.H. & Schiller, P.W. Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development. Pharm. Res. 28, 2669-2679 (2011).
17. Marcinek, D.J. & Conley, K.E. In vivo metabolic spectroscopy identifies deficits in mitochondrial quality and capacity in aging skeletal muscle. Clin. Pharmacol. Ther. 96, 669-671 (2014).
18. Reidenberg, M.M. Should administration of coenzyme Q10 be recommended to patients with congestive heart failure? Clin. Pharmacol. Ther. 96, 647-649 (2014).
19. Mortensen, S.A. & Mortensen, A.L. The mitochondria in heart failure: a target for coenzyme Q10 therapy? Clin. Pharmacol. Ther. 96, 645-647 (2014).
20. Sims, C.R., MacMillan-Crow, L.A. & Mayeux, P.R. Targeting mitochondrial oxidants may facilitate recovery of renal function during infant sepsis. Clin. Pharmacol. Ther. 96, 662-664 (2014).
21. Szeto, H.H & Birk, A.V. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin. Pharmacol. Ther. 96, 672-683 (2014).
22. Kloner, R.A. et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J. Am. Heart Assoc. 1, e001644 (2012).
23. Hansson, M.J. et al. Cyclophilin D-sensitive mitochondrial permeability transition in adult human brain and liver mitochondria. J. Neurotrauma 28, 143-153 (2011).
24. Hansson, M.J. et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembranes 36, 407-413 (2004).
25. Hersh, S.P. Fast-tracking the development of effective therapeutics in mitochondrial medicine. Clin. Pharmacol. Ther. 96, 641-643 (2014).